In-depth Exploration of the Pharmacological, Analytical, and Pharmaceutical Attributes of Irbesartan

Abstract

Irbesartan, an angiotensin II receptor blocker (ARB), has gained prominence in the management of hypertension and diabetic nephropathy due to its potent antihypertensive and Reno protective effects. This review provides a comprehensive overview of the pharmacological, analytical, and pharmaceutical characteristics of Irbesartan. Pharmacologically, Irbesartan selectively antagonizes the angiotensin II type 1 (AT1) receptors, leading to vasodilation, reduced aldosterone secretion, and consequently blood pressure lowering. The drug also exhibits favourable effects on renal function, making it a cornerstone therapy for diabetic nephropathy. Analytically, various chromatographic methods including high-performance liquid chromatography (HPLC) and Ultra-performance liquid chromatography (UPLC) have been developed and validated for the quantification of Irbesartan in biological samples and pharmaceutical formulations, owing to its importance in pharmacokinetic studies and quality control processes. Moreover, spectroscopic techniques such as UV-visible spectrophotometry have been utilized for Irbesartan determination due to their simplicity and cost-effectiveness. Pharmaceutical considerations encompass formulation strategies, stability studies, and bioavailability enhancement techniques aimed at ensuring the efficacy and safety of Irbesartan formulations. The regulatory approval of Irbesartan-containing products by major health authorities underscores its clinical significance and quality assurance.